H eart failure (HF) constitutes a major public health burden with an estimated prevalence of >5.7 million in the United States and >23 million worldwide. 1, 2 There was a striking increase in its prevalence from the 1970s through the 1990s, during which time it reached an epidemic level. 3, 4 Although recent reports suggest that the incidence of HF has plateaued in the general population and is decreasing in some groups, 1, 5, 6 an estimated 915 000 individuals are still diagnosed as having HF in the United States each year. Furthermore, because of the aging of the population and improved survival after diagnosis, the prevalence of HF is still increasing and is estimated to increase by 46% from 2012 to 2030, which will result in >8 million adults with a diagnosis of HF. 2, 7 To further understand the epidemiological characteristics and burden of HF, an assessment of the trends in its admission and mortality rates is imperative. More so, an insight into these trends serves as a quality metric for evaluating the advances made in healthcare delivery and national guidelines aimed at improving patient outcomes. Prior studies on trends in HF hospitalization and in-hospital mortality in the United States demonstrated a decline between 1998 and 2009. [8] [9] [10] However, there is a lack of evidence on recent trends in HF hospitalization outcomes after 2009 and detailed assessment of progress made after publication of national guidelines.
To address these gaps in knowledge, we therefore performed an in-depth analysis of the national trends in admission and in-hospital mortality in patients with HF with the goal of providing an assessment of the progress made during the past decade through concerted efforts, such as the periodic publication of national HF management guidelines by the American College of Cardiology (ACC)/American Heart Association (AHA) joint task force.
Methods Data Source
This study was conducted using the National Inpatient Sample (NIS) of the Health Care Utilization Project sponsored by the Agency for Healthcare Research and Quality. Details of the design and description of the NIS are available online. 11 Briefly, this nationally representative database, which represents the largest all-payer inpatient care database in the United States, contains yearly encounterlevel information of hospital stays compiled in a uniform format, with privacy protection of individual patients. NIS approximates a 20% stratified sample of discharges from nonfederal, short-term, general, and other specialty hospitals in the United States. To derive national estimates from the sample, the Agency for Healthcare Research and Quality provides a trend/discharge weight that accounted for the sampling design. The study was considered exempt from formal review by the Wayne State University (Detroit, MI) institutional review board because it involves a deidentified public database and the involved individuals did not receive a test material (ie, drug or device) as participants in the study.
Patient Population
We included all adult patients (aged ≥18 years) with a primary or secondary diagnosis of HF in the NIS database between 2001 and 2014. A primary HF diagnosis refers to hospitalizations mainly attributable to HF, whereas a secondary diagnosis refers to hospitalizations in patients with chronic HF who were admitted for reasons other than HF. These were identified via the following 
Covariates
Data on patient-and hospital-level characteristics were provided for each hospitalization in the NIS database. However, identifiable variables were not included to preserve both patient and hospital privacies. Patient-level factors, including demographics, diagnoses, comorbidities, in-hospital procedures, and disposition, as well as hospital-level factors, including bed size, location, and total number of hospitalizations, are available via the NIS database.
End Points
The main end points in this study were trends in admission and in-hospital mortality in patients admitted with a primary diagnosis of HF. In addition, we evaluated similar trends in patients admitted with a secondary diagnosis of HF. Inhospital mortality was available in the NIS data as a categorical variable (yes/no).
Statistical Analysis
National estimates, including measure of central tendencies, rates, and proportions, were calculated using the hospitallevel trend weights provided for the NIS by the Agency for Healthcare Research and Quality. To quantify comorbidities per hospitalization, we used the Deyo modification of the Charlson comorbidity index (ie, Charlson/Deyo score) to identify and classify coexisting conditions (Table S1 ). 13 Baseline characteristics were compared using the v 2 test
for categorical variables and the ANOVA or Kruskal-Wallis
Clinical Perspective
What Is New?
• From 2001 to 2014, there has been a significant decline in heart failure-related admissions and in-hospital mortality in the United States.
• During the study period, we found that the greatest decline in these hospitalization outcomes coincided with the publication of the 2005 American College of Cardiology/ American Heart Association heart failure management guidelines. Table S2 ). The rates of these primary HF admissions declined from 563 per 100 000 people in 2001 to 398 per 100 000 people in 2014 ( Figure 1A) , with an average annual decline of 3% (95% confidence interval [CI], 2.5%-3.5%; P<0.001; Table 2 ).
When we evaluated rates of decline within the 3 intervals of the ACC/AHA HF guidelines, there was a decreasing trend within each interval, but the magnitude of the decline was higher in the later intervals (ie, average annual rate of decline was 1.1% [95% CI, 0.18%-1.9%; P=0.02] for the first interval, 3.4% [95% CI, 2.4%-4.4%; P<0.001] for the second interval, and 4.3% [95% CI, 3.9%-5.9%; P<0.001] for the third interval) ( Figure 1A ). We found a significant change in trend after the 2005 guidelines compared with before the guidelines. Specifically, we found that the magnitude of the average annual rate of decline in primary HF admission was 2.4% (95% CI, 0.39%-4.4%; P=0. 
Mortality
In-hospital mortality among patients hospitalized with a primary diagnosis of HF declined from 4.5% in 2001 to 2.9% in 2014, although the rate of decline gradually diminished in the past few years of the study period ( Figure 1B) . Overall, the average annual rate of decline in mortality in patients with a primary diagnosis of HF was 3.5% (95% CI, 2.9%-4.0%; P<0.001; Table 2 ). Compared with those who survived to hospital discharge, those who died were older (70.4% versus 51.2% were aged ≥75 years), were more likely to be white (78.4% versus 67.9%), had a higher Charlson/Deyo comorbidity score (59.4% versus 53.8% had a score of ≥2), were enrolled in the Medicare insurance program (81.5% versus 75%), and were in rural (17.5% versus 16.1%) and urban (44.3% versus 43.5%) nonteaching hospitals (Table S2 ). In addition, mortality was highest within the first 2 days of admission, decreased to a nadir on days 3 and 4, and trended up afterwards ( Figure 2 ). When we evaluated changes in the in-hospital mortality rate in the 3 time intervals of the ACC/AHA HF guidelines, the observed in-hospital mortality rate decreased in each interval, but the magnitude of the decline diminished in the later intervals: the average annual rate of decline was 4.2% (95% CI,3.9%-4.5%; P<0. In stratified analysis (Table 4) , in-hospital mortality was higher among patients aged ≥65 years compared with <65 years, although there was a slight closing of the gap in the later years compared with the earlier part of the study period ( Figure 3A) . Closing of the gap was mainly attributable to a faster rate of decline in in-hospital mortality among patients aged ≥65 years, with an average annual decline of 3.2% (95% CI, 2.8%-3.7%; P<0.001) compared with 2.3% (95% CI, 1.4%-4.2%; P<0.001) among patients aged <65 years. In addition, the decline in in-hospital mortality plateaued among patients aged <65 years, whereas it was still decreasing among patients aged ≥65 years in the last interval of the study period (ie, 2010-2014). When we stratified analysis by sex, we found that in-hospital mortality was higher in men at the beginning of the study (ie, year 2001) ( Figure 3B ). However, the rate of decline was faster in men (5.5% [95% CI, 5.0%-6.3%]; P<0.001) than in women (3.2% [95% CI, 2.5%-3.9%]; P<0.001) during the first interval, and the apparent sex gap seems to have closed by the third interval. Last, stratified analysis by race showed that in-hospital mortality was highest Figure 4A ). When we evaluated the secondary HF admission rates in the 3 time intervals of the ACC/AHA guidelines, there was a significant change in trend after the publication of the guidelines in 2005 but no significant change after 2009 ( Figure 4A , Table 2 ; the admission rates plateaued after the 2009 guidelines (ie, third interval). Across the 3 intervals (from first to third), the age at admission decreased (eg, percentage of admissions with age ≥65 years decreased from 78.7% to 73.8%; Table 5 ). Also, there was a decreasing percentage of women (55.9% to 52.4%), whites (77% to 72.7%), Medicare beneficiaries (79.7% to 77.8%), and rural (17.2% to 13.2%) and urban (45.5% to 37.7%) nonteaching hospital admissions. However, the degree of comorbid conditions per hospitalization, as measured by the Charlson/Deyo comorbidity score, increased over the years (eg, hospitalizations with a score of ≥2 increased from 68.1% in the first interval to 78.3% in the third interval). Last, there was a decrease in the median (interquartile range) length of stay over the 3 intervals from 6.0 (6.0) days in the first interval to 5.0 (5.0) days in the third interval.
In-hospital mortality in patients with a secondary diagnosis of HF declined from 8.3% in 2001 to 5.6% in 2014 ( Figure 4B ). The average annual rate of decline was 3.7% (95% CI, 3.3%-4.2%; P<0.001; Table 2 ). Compared with those who survived to hospital discharge, those who died were older (66.4% versus 53% were aged ≥75 years) and were less likely to be In addition, similar to HF as a primary diagnosis, mortality was highest within the first 2 days of admission, decreased to a nadir on days 3 and 4, and trended up afterwards (Figure 2) . Overall, patients with HF were more likely to die while hospitalized for another reason (ie, HF as a secondary diagnosis) than while hospitalized for HF.
When we evaluated the change in the in-hospital mortality in each of the 3 time intervals of the ACC/AHA HF guidelines, the rate decreased in each interval, but the magnitude of the decline was greatest in the second interval. The average annual rate of decline was 3.4% (95% CI, 2.7%-4.0%; P<0.001) for the first interval, 5.4% (95% CI, 4.7%-6.2%; P<0.001) for the second interval, and 1.3% (95% CI, 0.27%-2.4%; P=0.02) for the third interval (Table 2 ). There was a significant change in trends after both guidelines were published, but only after 2005 was the trend a decline ( Figure 4B ).
Discussion
In this nationally representative sample of hospital admissions in the United States, we found that, despite an increase in comorbidity burden, the rate of hospital admission primarily for HF declined from 2001 through 2014 while the trend in HF as a secondary diagnosis initially increased to a peak in 2006 but decreased afterwards to a somewhat plateau. In addition, the rate of in-hospital mortality among patients admitted with either a primary or a secondary diagnosis of HF declined from 2001 through 2014. Last, we found that, after publication of the 2005 guidelines, there was a further decrease in the trend of HF admissions as a primary or a secondary diagnosis as well as in-hospital mortality when HF was a secondary diagnosis.
At the beginning of the study period, the observed rate of in-hospital mortality among hospitalizations with a primary diagnosis of HF was more in patients aged ≥65 years, males, and whites. However, towards the end of the study period, there was slight closing of the gap between patients ≥65 years and those <65 years, whereas the sex gap was no longer apparent. In contrast, the racial gap seemed to persist, although the trends in Hispanic and Asian populations had plateaued, whereas there was still some decreasing trend among white and black race towards the end of the study period. Similar to prior studies, [17] [18] [19] we found that the observed rate of in-hospital mortality for primary HF admissions was higher among whites compared with other races. A possible explanation for this may include a higher rate of readmission among other races (thereby increasing their number of hospitalizations) compared with whites or a higher mean age at hospitalization for whites (76 years versus 63 years [for blacks], 69 years [for Hispanics], and 72 years [for Asians] in our analysis of NIS data). However, this higher risk of in-hospital mortality persisted in whites after adjusting for age, repeated hospitalization, and other possible confounding factors in prior studies. 17, 18 Hence, further studies are needed to clearly identify the determinants of this racial disparity. Our findings build on and considerably expand on results of prior studies on the trends in HF admissions from 1998 through 2009. [8] [9] [10] Notably, we showed that the rate of Potential limitations of this study should also be considered. First, because of the observational nature of the study, it is impossible to claim that the change in trends after publication of the guidelines was as a result of the guidelinedirected care. In other words, our findings represent an association, but not causation, because other variables not evaluated in this study could have also contributed to this change in trend. Second, HF hospitalizations were identified via ICD-9-CM codes for which it is possible that the coding preference has changed during the study period. We, however, mitigate against this by identifying our patient population using an extensive number of ICD-9-CM codes that were recommended by the ACC/AHA task force on performance measure. Third, the NIS is a sampling of hospitalizations rather than unique patients, which may contribute >1 hospitalization from readmissions. This is a general limitation of most hospital discharge databases, such as NIS, which, unfortunately, could not be adjusted for because patients are deidentified in the database. Our analysis, therefore, represents a composite of both first admission (during the study period) and readmissions, which is of great value in contemporary analysis of HF data. Hence, our admission rates should be interpreted as number of total hospitalizations per US population, whereas mortality rates represent mortalityassociated hospitalizations per total hospitalizations in that year.
In summary, despite an increase in comorbidity burden, primary HF hospitalization and HF-associated (ie, HF as the primary or the secondary diagnosis) in-hospital mortality declined in the United States between 2001 and 2014. There seems to be a further decline in HF-associated admissions and in-hospital mortality among patients with a secondary diagnosis of HF after the publication of the 2005 ACC/AHA HF management guidelines compared with the preceding trend. However, little further improvement was observed beyond 2009 during the study period.
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